Industries > Pharma > Smoking Cessation Drugs: World Market Prospects 2013-2023
Smoking Cessation Drugs: World Market Prospects 2013-2023
Anti-smoking drug revenues will expand – you see what's most likely to succeed
How much revenue can medicines to treat smoking generate? Visiongain's updated report gives you predictions, helping you stay ahead. There you see financial results, R&D trends, opportunities, and commercial potential.
In that new study you discover forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess technologies, competition, and expected developments for treating tobacco addiction. Find prospects there.
Read on to explore those products and see what their future market could be worth.
Forecasts from 2013-2023 and other analyses to help you find opportunities
Besides revenue forecasting to 2023, our analysis shows recent results, growth rates, and market shares. There you discover original analysis, seeing commercial outlooks and developments (R&D). You also get 60 tables, 36 charts, and four interviews.
Discover what's happening in that industry, using our report to find data you need
In that study you hear what's happening for smoking medications, learning where needs and money exist. Try our report now, seeing how you and your organisation can gain.
Avoid falling behind, missing business or losing influence. Instead, discover information you need to stay ahead. Our work explains, helping your research, analyses, and decisions.
The following sections, then, show what you get in that new investigation.
Sales predictions for the world market and submarkets
Discover in our report overall world revenue to 2023 for smoking-cessation drugs. You also find individual revenue forecasts for therapeutic submarkets at world level:
• Over-the-counter medicines (OTC)
• Prescription drugs (Rx)
• Nicotine replacement therapies (NRT)
• Nicotine receptor partial agonists (NRPA)
How will sales of those therapies expand? Which classes of treatments will generate most money? There you assess prospects for revenue growth, seeing where you can benefit.
You also discover sales predictions by agent, seeing how they can succeed.
Revenue predictions for top products – see what's possible
How will those anti-addiction medicines perform to 2023 at world level? Our report forecasts individual revenues of six leading brands:
• NiQuitin/Nicabate/NicoDerm CQ
There, from 2013, you discover how high sales can go. Investigate opportunity. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.
You find geographical revenue predictions too.
National markets – where will highest revenues and growth occur?
In developed and developing countries, anti-smoking therapy will give opportunities to pharmaceutical companies. You see where and how, from 2013, understanding potential.
In our study you find individual revenue forecasts to 2023 for 11 national markets:
• United States (US)
• EU leaders – Germany, France, the UK, Italy, and Spain (EU5)
• BRIC countries – Brazil, Russia, India, and China.
There you find countries with highest revenues and potential sales growth. Our work explains. You see the future of those products, appraising progress and discovering what it means, including emerging trends.
Issues affecting developers, producers, and sellers of anti-smoking medicines
The report explains forces affecting that industry and market from 2013, including these:
• Nicotine vaccines
• Monoamine oxidase inhibitors
• Cannabinoid receptor-1 antagonists
• Dopamine D3 antagonists
• Opiate antagonists
• Other smoking cessation aids in testing.
There you assess research and development (R&D), finding advances and outlooks for business. You also explore OTC switching and governmental support of medicines treating tobacco use, including their reimbursement. Discover what the present and future hold.
Companies and overall 2017 market value – how high can sales go?
From 2013, treatments for cigarette smoking hold potential for investments, medical advances, and higher revenues. Our work predicts the overall world market will reach $2.5bn in 2017, with further expansion to 2023.
That report shows you what technologies and organisations hold greatest potential. In particular, you explore these companies:
• GlaxoSmithKline (GSK)
• Johnson & Johnson
Examine rising players, too, including Celtic Pharma, Selecta Biosciences, Aradigm, Extab Corporation, and Embera NeuroTherapeutics. Also, find interviews with three companies.
See what's possible in that industry. Our investigation explains the potential of its market, helping you stay ahead.
Information found nowhere else – discover the future of those neurological treatments
Through knowledge such as this, our new report helps you get recognition for insight:
• Revenues to 2023 at world level, with forecasting of 5 submarkets and 6 products – explore prospects for investments and sales
• Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia – investigate countries for revenues and expected growth
• Prospects for companies – assess portfolios, results, R&D activities, and outlooks for future success.
Smoking Cessation Drugs: World Market Prospects 2013-2023 gives independent analysis. There you receive competitive intelligence found only in our work. That study helps you find the money and show your authority on those technologies and their potentials. Gain now.
Anti-smoking agents – find commercial outlooks by ordering now
Our new report is for everyone investigating treatments for the central nervous system (CNS) and addictions. There you discover revenue forecasts to 2023, with discussions. Avoid missing out – please order now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
To view free sample pages of this report please click here